相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer
Janielle P. Maynard et al.
MOLECULAR CANCER RESEARCH (2020)
RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model
Shayna E. Thomas-Jardin et al.
PROSTATE (2020)
Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
Siddharth Gupta et al.
HORMONES & CANCER (2020)
Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence
Haley C. Dahl et al.
PLOS ONE (2020)
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer
Yanjing Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1
Rachana Patel et al.
EMBO MOLECULAR MEDICINE (2018)
Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2-and CXCL8-mediated cancer cell migration
Bianca Cioni et al.
MOLECULAR ONCOLOGY (2018)
Identification of an IL-1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR- PCa cells
Shayna E. Thomas-Jardin et al.
PROSTATE (2018)
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Florian Handle et al.
MOLECULAR CANCER THERAPEUTICS (2018)
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Arianna Calcinotto et al.
NATURE (2018)
Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer
Chao Wang et al.
CLINICAL CANCER RESEARCH (2018)
Expression of STAT3 in Prostate Cancer Metastases
Nicholas Don-Doncow et al.
EUROPEAN UROLOGY (2017)
Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis
Hongmei Dong et al.
JOURNAL OF PATHOLOGY (2017)
Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT
Qiuli Liu et al.
CELL DEATH & DISEASE (2017)
IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2
Constanze Merz et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells
Florian Handle et al.
MOLECULAR CANCER RESEARCH (2016)
Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth
Takashi Kawahara et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer
V. T. Baron et al.
BRITISH JOURNAL OF CANCER (2015)
Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals
Qiang Dang et al.
MOLECULAR ONCOLOGY (2015)
Niclosamide Suppresses Cell Migration and Invasion in Enzalutamide Resistant Prostate Cancer Cells via Stat3-AR Axis Inhibition
Chengfei Liu et al.
PROSTATE (2015)
Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling
Anne Schroeder et al.
CANCER RESEARCH (2014)
IL-1β Induces p62/SQSTM1 and Represses Androgen Receptor Expression in Prostate Cancer Cells
M. A. Chang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2014)
Inhibition of Constitutively Active Stat3 Reverses Enzalutamide Resistance in LNCaP Derivative Prostate Cancer Cells
Chengfei Liu et al.
PROSTATE (2014)
Generation of Prostate Tumor-Initiating Cells Is Associated with Elevation of Reactive Oxygen Species and IL-6/STAT3 Signaling
Yi Qu et al.
CANCER RESEARCH (2013)
The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer
Joice Rocha et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Interleukin-6 and Oncostatin-M Synergize with the PI3K/AKT Pathway to Promote Aggressive Prostate Malignancy in Mouse and Human Tissues
Daniel A. Smith et al.
MOLECULAR CANCER RESEARCH (2013)
Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer
S. Ha et al.
ONCOGENE (2013)
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
T-H Lin et al.
CELL DEATH & DISEASE (2013)
IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR
A. Rojas et al.
ONCOGENE (2011)
Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells
Jae Yeon Chun et al.
CLINICAL CANCER RESEARCH (2009)
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor
Kamilla Malinowska et al.
ENDOCRINE-RELATED CANCER (2009)
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2
Siting Feng et al.
MOLECULAR CANCER THERAPEUTICS (2009)
A Transcription-Independent Function of FOXO1 in Inhibition of Androgen-Independent Activation of the Androgen Receptor in Prostate Cancer Cells
Ping Liu et al.
CANCER RESEARCH (2008)
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation
Angela Seaton et al.
CARCINOGENESIS (2008)
Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer
Shinako Araki et al.
CANCER RESEARCH (2007)
Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells
Christopher F. MacManus et al.
MOLECULAR CANCER RESEARCH (2007)